UCLan Research Institute For Global HEalth and Wellbeing - LIFE

The UCLan Research Institute For Global Health and Wellbeing (LIFE) brings together researchers from the faculties of Health and Wellbeing and Clinical and Biomedical Sciences at UCLan to enhance and enable globally relevant health and wellbeing research.

In line with UCLan’s research and internationalisation strategies, the Institute will foster new, and enhance existing, global health research collaborations in order to extend reach, reputation and impact.   It will achieve this through a range of activities including supporting researchers to develop high quality funding applications, to deliver research programmes and encouraging researchers at all stages of their careers to engage at a global level. The Institute, led by Professor Dame Caroline Watkins began in Jan 2018, with the support of key staff Professor StJohn Crean, Professor Nigel Harrison, Rachel Georgiou and Professor Cathy Jackson . For further information please contact Globalhealth@uclan.ac.uk

Professor Dame Caroline Watkins tells us about the new Research Institute:

Better Outcomes for Everybody (BOFE)

The prevalence of asthma has been increasing, and about 400 million people will have asthma by 2025. Chronic Obstructive Pulmonary Disease (COPD) was the fourth leading cause of death worldwide in 2015 and will become the third by 2030. Asthma accounts for an economic loss of €72 billion and COPD of €141 billion annually in 28 countries of the European Union.

A previous study conducted in Italy demonstrated the effectiveness and cost-effectiveness of a pharmacist-led intervention for Asthma patients but not for patients suffering from COPD.

BOFE is an international multicentre randomised controlled trial evaluating the effectiveness and cost-effectiveness of a bespoke pharmacist-led intervention for Asthma and COPD patients using Artificial Intelligence (AI) and Internet of Medical Things (IoMT).

All patients in the intervention arm will receive a bespoke pharmacists-led intervention; some of them will receive more intensive monitoring based on AI and IoMT. Patients in the control arm will receive standard care.

The outcomes of the study are aiming at improving the clinical conditions, quality of life, adherence to medication treatments, medicine optimisation, therefore, improving health outcomes and reducing costs to the NHS and the Society.

The partner institutions are the Universities of Central Lancashire (UK), Oxford (UK) and Catania (Italy).

SOFAD Gruppo Farvima fully funds the project.

To find out more please contact Professor Andrea Manfrin.